BRIEF published on 11/13/2025 at 18:02, 1 month 4 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 1 month 18 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 2 months 17 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 2 months 17 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 2 months 17 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 3 months 19 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 3 months 19 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 5 months ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 5 months ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 5 months ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
Published on 12/17/2025 at 15:00, 4 hours 39 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 5 hours 39 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 6 hours 4 minutes ago Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 6 hours 24 minutes ago Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers
Published on 12/17/2025 at 13:00, 6 hours 39 minutes ago Gold Terra Provides a Summary of 2025 Achievements and 2026 Plan
Published on 12/17/2025 at 19:10, 29 minutes ago Holand Automotive Group Announces the sale of Ferrari Rancho Mirage to Lapis Automotive Group
Published on 12/17/2025 at 18:39, 1 hour ago EQS-Adhoc: centrotherm international AG: Centrotherm AcquiCo AG submits request for the squeeze-out of minority shareholders of centrotherm international AG
Published on 12/17/2025 at 18:05, 1 hour 34 minutes ago Valour Inc. Launches Constant Leveraged Bitcoin and Ethereum ETPs on Spotlight Stock Market
Published on 12/17/2025 at 17:32, 2 hours 6 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: Michael Höllerer will succeed Johann Strobl as CEO of RBI on 1 July 2026
Published on 12/17/2025 at 18:00, 1 hour 39 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
Published on 12/17/2025 at 17:51, 1 hour 48 minutes ago Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure
Published on 12/17/2025 at 17:50, 1 hour 49 minutes ago The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.
Published on 12/17/2025 at 17:45, 1 hour 54 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2025
